Clinical Trial Update: RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is planned to evaluate RC48 (disitamab vedotin) in combination with chemotherapy for HER2-positive advanced/metastatic breast cancer in patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RC48 (disitamab vedotin) (disitamab vedotin)

Snippet

Sponsor: Fudan University | Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING